Kantonsspital St. Gallen

Running trials

• Recruiting

  MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.

  NCT07574047· Phase 2· Swiss Cancer Institute· Source

• Recruiting

  Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)

  NCT07149649· Phase 2/3· Swiss Cancer Institute· Source

• Recruiting

  Pharmacoscopy for Patients With Refractory Primary Brain Tumors

  NCT06804655· Phase 2· University of Zurich· Source

• Recruiting

  A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

  NCT07623200· Phase 3· Incyte Corporation· Source

• Recruiting

  Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC

  NCT07158489· Phase 2· Swiss Cancer Institute· Source

• Not yet recruiting

  Redo-Pulmonary Vein Isolation With Versus Without Posterior Wall Ablation - The REDO-PIFPAF-PFA Study

  NCT07745543· University Hospital, Basel, Switzerland· Source

• Recruiting

  ToPanc Trial: Survival After Total Versus Partial Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic Head, Distal Cholangiocarcinoma, and Ampullary Cancer

  NCT06801899· Insel Gruppe AG, University Hospital Bern· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07577856· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  NCT07577843· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Terbinafine for Biochemically Recurrent Prostate Cancer (TerbinaPro)

  NCT07365423· Phase 2· Swiss Cancer Institute· Source

• Recruiting

  A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2

  NCT07203053· Phase 2· ETOP IBCSG Partners Foundation· Source

• Recruiting

  Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

  NCT07020065· Phase 2· Swiss Cancer Institute· Source

• Recruiting

  A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  NCT07361497· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  Transarterial Chemoembolization (TACE) Plus ABCB1 Inhibition Versus TACE Alone in Patients With Hepatocellular Carcinoma

  NCT07302919· Phase 2/3· University Hospital, Basel, Switzerland· Source

• Recruiting

  Targeting Real World Usage In Stroke Treatment

  NCT07474935· Phenox GmbH· Source

• Recruiting

  Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis

  NCT07217587· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

  NCT06932562· Phase 3· European Myeloma Network B.V.· Source

• Recruiting

  Early Detection and IntervenTion in Heart Failure

  NCT07731490· University Hospital, Basel, Switzerland· Source

• Not yet recruiting

  Tideglusib for the Treatment of Amyotrophic Lateral Sclerosis

  NCT05105958· Phase 2· University of Zurich· Source

• Recruiting

  A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD

  NCT06847542· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

  NCT07100080· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue Sarcoma (TNT-HYPE)

  NCT06835049· Phase 2· Swiss Cancer Institute· Source

• Active, not recruiting

  A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

  NCT07076121· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  Fiber-Boost Randomized Controlled Trial

  NCT07483112· Cantonal Hospital of St. Gallen· Source

• Active, not recruiting

  A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07196748· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Underweight, Overweight, and Linear Growth of Childhood Cancer Patients - the Growth Study

  NCT07750444· Fabiën Belle· Source

• Recruiting

  Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

  NCT07106762· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

  NCT06926868· Phase 2/3· Bristol-Myers Squibb· Source

• Active, not recruiting

  A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

  NCT06880744· Phase 3· AbbVie· Source

• Recruiting

  A Space-expanding Shield in Decompressive Hemicraniectomy for Stroke

  NCT06638385· Insel Gruppe AG, University Hospital Bern· Source

• Recruiting

  Primary and Acquired Resistance to Targeted Treatment in BRAF V600E-mutated Metastatic Colorectal Cancer

  NCT07617610· Swiss Cancer Institute· Source

• Recruiting

  Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  NCT06881784· Phase 3· Revolution Medicines, Inc.· Source

• Recruiting

  OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy

  NCT06466382· Swiss GO Trial Group· Source

• Recruiting

  Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake

  NCT06571149· Phase 4· Insel Gruppe AG, University Hospital Bern· Source

• Recruiting

  A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

  NCT06615479· Phase 3· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• Recruiting

  Reduce Tobacco Use in People Living With HIV in Switzerland

  NCT06789692· University Hospital, Basel, Switzerland· Source

• Recruiting

  Extended vs. No Pelvic Lymph Node Dissection During Radical Prostatectomy. DISSECTION 2.0.

  NCT06776172· University Hospital, Basel, Switzerland· Source

• Recruiting

  A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

  NCT06284317· Phase 3· ETOP IBCSG Partners Foundation· Source

• Active, not recruiting

  Nipocalimab in Moderate to Severe Sjogren's Disease

  NCT06741969· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

  NCT06655155· Phase 2· argenx· Source

• Recruiting

  Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  NCT06401980· Phase 2· Swiss Cancer Institute· Source

• Active, not recruiting

  A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

  NCT06384261· Phase 2· OncoVerity, Inc.· Source

• Active, not recruiting

  A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

  NCT06468228· Phase 3· AbbVie· Source

• Recruiting

  SASL Swiss Cirrhosis Cohort

  NCT06092385· University Hospital, Basel, Switzerland· Source

• Recruiting

  A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

  NCT06203210· Phase 3· Daiichi Sankyo· Source

• Recruiting

  Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy

  NCT05976685· Insel Gruppe AG, University Hospital Bern· Source

• Recruiting

  Shunt-dependency After aSAH - Role of Early Hyperglycaemia in CSF and Blood

  NCT06486909· Isabel Hostettler· Source

• Recruiting

  Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants

  NCT06556446· Insel Gruppe AG, University Hospital Bern· Source

• Recruiting

  Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC

  NCT05718323· Phase 2· ETOP IBCSG Partners Foundation· Source

• Recruiting

  A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

  NCT06091254· Phase 3· Regeneron Pharmaceuticals· Source

Showing 50 of 127.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer11 recruiting
• Stroke7 recruiting
• Atrial fibrillation4 recruiting
• Prostate cancer4 recruiting
• Brain aneurysm3 recruiting
• HIV3 recruiting
• Melanoma3 recruiting
• Multiple myeloma3 recruiting
• Glioblastoma2 recruiting
• Liver and biliary tract cancer2 recruiting
• Metastatic breast cancer2 recruiting
• Ovarian cancer2 recruiting
• ALS (motor neurone disease)1 recruiting
• ANCA-associated vasculitis1 recruiting
• Bladder cancer1 recruiting
• Childhood cancers1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Colorectal cancer1 recruiting
• Congenital heart disease1 recruiting
• Crohn's disease1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Follicular lymphoma1 recruiting
• Heart failure1 recruiting
• Hepatitis B1 recruiting
• Hepatitis C1 recruiting
• Hydrocephalus1 recruiting
• Liver cirrhosis1 recruiting
• Macular degeneration1 recruiting
• Meningioma1 recruiting
• Multiple sclerosis1 recruiting
• Myasthenia gravis1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Pancreatic cancer1 recruiting
• Primary biliary cholangitis1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Sarcoma1 recruiting
• Triple-negative breast cancer1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Completed

  Quality of Life After Transanal Total Mesorectal Excision Compared to Traditional Total Mesorectal Excision

  NCT06505863· Cantonal Hospital of St. Gallen· Source

• Terminated

  A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)

  NCT06113328· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Safety and Efficacy of Intra-arterial Tenecteplase for Noncomplete Reperfusion of Intracranial Occlusions

  NCT05499832· Phase 3· Insel Gruppe AG, University Hospital Bern· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001)

  NCT05594043· Phase 1· Merck Sharp & Dohme LLC· Source

• Completed

  A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

  NCT05559580· Phase 2· Boehringer Ingelheim· Source

• Completed

  A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

  NCT05601882· Phase 3· AbbVie· Source

• Recruiting

  A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

  NCT05131022· Phase 1· Nurix Therapeutics, Inc.· Source

• Completed

  A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)

  NCT05259033· Phase 3· Novo Nordisk A/S· Source

• Terminated

  Generate Real World Data On Tofacitinib Induction Therapy and Changes In Clinical and Patient Reported Outcomes.

  NCT05069259· Pfizer· Source

• Completed

  A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy in Switzerland and Austria Receiving Oral Venetoclax Tablets

  NCT05215639· AbbVie· Source

• Completed

  A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis

  NCT05081557· AbbVie· Source

• Completed

  Group Psychotherapy in Long COVID

  NCT06726772· Cantonal Hospital of St. Gallen· Source

• Completed

  A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland

  NCT04989907· Takeda· Source

• Terminated

  Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC

  NCT04629781· Phase 1· Swiss Cancer Institute· Source

• Completed

  A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer.

  NCT04855929· Phase 1· Anaveon AG· Source

• Terminated

  A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

  NCT04832854· Phase 2· Hoffmann-La Roche· Source

• Completed

  Cardiovascular and Renal Treatment in Heart Failure Patients With Hyperkalaemia or at High Risk of Hyperkalaemia

  NCT04864795· Vifor (International) Inc.· Source

• Completed

  SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II

  NCT04480372· Phase 2· Swiss Cancer Institute· Source

• Completed

  A Study to Assess the Potential Impact of Disease Modifying Therapies on COVID-19 Outcomes and the Antibody Response Following an Infection With SARS-CoV-2 in Patients With Multiple Sclerosis Within the Swiss Multiple Sclerosis Cohort.

  NCT04760990· University Hospital, Basel, Switzerland· Source

• Completed

  A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid Arthritis

  NCT04497597· AbbVie· Source

• Completed

  Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.

  NCT03993678· Phase 1/2· Swiss Cancer Institute· Source

• Completed

  ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma

  NCT04245085· Phase 2· ETOP IBCSG Partners Foundation· Source

• Completed

  Performance of 177Lu-PSMA-I&T for RLT in mCRPC - Prospective Multicenter Swiss Registry Study

  NCT06830408· University Hospital, Basel, Switzerland· Source

• Completed

  Eurythmy Therapy (ERYT) as a Treatment Option for Fatigue in Metastatic Breast Cancer Patients

  NCT04024267· University of Bern· Source

• Completed

  A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer

  NCT04294810· Phase 3· Hoffmann-La Roche· Source

• Completed

  Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)

  NCT04223778· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors

  NCT03945773· Phase 2· Ipsen· Source

• Terminated

  A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)

  NCT04044690· Phase 3· CSL Behring· Source

• Completed

  A Superiority Trial of the SUPERA Peripheral Stent System in Patients With Femoro-popliteal Artery Disease

  NCT03941314· Kantonsspital Winterthur KSW· Source

• Completed

  Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

  NCT03867084· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma

  NCT03762018· Phase 3· ETOP IBCSG Partners Foundation· Source

• Completed

  A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

  NCT03915964· Phase 4· Eli Lilly and Company· Source

• Completed

  Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

  NCT03797326· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

  NCT03734029· Phase 3· Daiichi Sankyo· Source

• Completed

  Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)

  NCT03675737· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT03524092· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)

  NCT03516981· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

  NCT03353831· Phase 3· AGO Research GmbH· Source

• Completed

  An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

  NCT03518086· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Post-Market BTVA Registry

  NCT03318406· Uptake Medical Technology, Inc.· Source

• Completed

  Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma

  NCT03297593· Phase 2· Swiss Cancer Institute· Source

• Recruiting

  Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting

  NCT03342144· AbbVie· Source

• Completed

  Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M

  NCT03133546· Phase 2· ETOP IBCSG Partners Foundation· Source

• Completed

  A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

  NCT03104400· Phase 3· AbbVie· Source

• Terminated

  ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.

  NCT02933801· Phase 2· Swiss Cancer Institute· Source

• Completed

  Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

  NCT02950051· Phase 3· German CLL Study Group· Source

• Completed

  Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)

  NCT02572843· Phase 2· Swiss Cancer Institute· Source

• Completed

  Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

  NCT02576496· Phase 1· Mundipharma Research Limited· Source

• Completed

  A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma

  NCT02451943· Phase 3· Eli Lilly and Company· Source

Showing 50 of 60.

Conditions

Diseases this institution publishes on or runs trials for.

• Narcolepsy3 works · 0 trials